Zydus Cadila gets USFDA nod for Tofacitinib ER tablets

Published On 2021-08-23 07:56 GMT   |   Update On 2021-08-23 08:00 GMT
Advertisement

Ahmedabad: Drugmaker, Zydus Cadila, today announced that the company has received final approval from the United States Food & Drug Administration (USFDA) to market Tofacitinib extended-release tablets, 11 mg and 22 mg in the United States (ANDA-214264 and US RLD: XELJANZ XR).

Zydus was the first abbreviated new drug application (ANDA) filer on Tofacitinib extended-release tablets 22 mg and currently holds 180-day exclusivity on this strength, the company said in a release.

The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad. 

Tofacitinib extended-release tablets had annual sales of approximately $2,082 million in the United States for the year ending June 2021 according to IQVIA data.

The group now has 321 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04

Read also: First: Zydus Cadila needle-free COVID vaccine gets DCGI nod, PM Modi says momentous feat

Zydus Cadila is a global pharmaceutical company headquartered in Ahmedabad, India.

The company discovers, develops, manufactures, and markets a broad range of healthcare therapies.





Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News